Sit Investment Associates Inc. Acquires 11,050 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Sit Investment Associates Inc. raised its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 104.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,600 shares of the company’s stock after purchasing an additional 11,050 shares during the quarter. Sit Investment Associates Inc. owned 0.08% of Establishment Labs worth $995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. R Squared Ltd bought a new position in Establishment Labs during the fourth quarter valued at about $36,000. KLP Kapitalforvaltning AS bought a new position in shares of Establishment Labs during the 4th quarter valued at approximately $161,000. Handelsbanken Fonder AB grew its position in shares of Establishment Labs by 32.3% during the 4th quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company’s stock valued at $378,000 after acquiring an additional 2,000 shares during the period. Verition Fund Management LLC raised its holdings in shares of Establishment Labs by 22.8% in the 3rd quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock worth $407,000 after purchasing an additional 1,746 shares during the period. Finally, HighTower Advisors LLC lifted its stake in Establishment Labs by 32.5% in the third quarter. HighTower Advisors LLC now owns 10,311 shares of the company’s stock valued at $446,000 after purchasing an additional 2,529 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Stephens reissued an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.40.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $32.30 on Monday. The firm has a market cap of $931.73 million, a P/E ratio of -12.52 and a beta of 0.77. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The company’s 50 day moving average is $36.67 and its 200-day moving average is $40.61. Establishment Labs Holdings Inc. has a 12-month low of $28.16 and a 12-month high of $60.12.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to analysts’ expectations of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.